The FDA has approved Guardant Health's Guardant360 Dx to be used to profile tumor mutations in patients with any solid malignant tumor.
Guardant's liquid biopsy assay OK'd for tumor profiling
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.